Center for Case Management, Natick, MA.
Division of Pulmonary and Critical Care Medicine, Baystate Medical Center, Springfield, MA.
Crit Care Med. 2021 Jul 1;49(7):e701-e706. doi: 10.1097/CCM.0000000000005012.
OBJECTIVES: To compare Acute Physiology and Chronic Health Evaluation-IV-adjusted mortality and length of stay outcomes of adult ICU patients who tested positive for coronavirus disease 2019 with patients admitted to ICU with other viral pneumonias including a subgroup with viral pneumonia and concurrent acute respiratory distress syndrome (viral pneumonia-acute respiratory distress syndrome). DESIGN: Retrospective review of Acute Physiology and Chronic Health Evaluation data collected from routine clinical care. SETTING: Forty-three hospitals contributing coronavirus disease 2019 patient data between March 14, and June 17, 2020, and 132 hospitals in the United States contributing data on viral pneumonia patients to the Acute Physiology and Chronic Health Evaluation database between January 1, 2014, and December 31, 2019. PATIENTS AND MEASUREMENTS: One thousand four hundred ninety-one patients with diagnosis of coronavirus disease 2019 infection and 4,200 patients with a primary (n = 2,544) or secondary (n = 1,656) admitting diagnosis of noncoronavirus disease viral pneumonia receiving ICU care. A subset of 202 viral pneumonia patients with concurrent acute respiratory distress syndrome was examined separately. INTERVENTIONS: None. MAIN RESULTS: Mean age was 63.4 for coronavirus disease (p = 0.064) versus 64.1 for viral pneumonia. Acute Physiology and Chronic Health Evaluation-IV scores were similar at 56.7 and 55.0, respectively (p = 0.060), but gender and ethnic distributions differed, as did Pao2 to Fio2 ratio and WBC count at admission. The hospital standardized mortality ratio (95% CI) was 1.52 (1.35-1.68) for coronavirus disease patients and 0.82 (0.75-0.90) for viral pneumonia patients. In the coronavirus disease group, ICU and hospital length of stay were 3.1 and 3.0 days longer than in viral pneumonia patients. Standardized ICU and hospital length of stay ratios were 1.13 and 1.46 in the coronavirus disease group versus 0.95 and 0.94 in viral pneumonia patients. Forty-seven percent of coronavirus disease patients received invasive or noninvasive ventilatory support on their first ICU day versus 65% with viral pneumonia. Ventilator days in survivors were longer in coronavirus disease (10.4 d) than in viral pneumonia (4.3 d) patients, except in the viral pneumonia-acute respiratory distress syndrome subgroup (10.2 d). CONCLUSIONS: Severity-adjusted mortality and length of stay are higher for coronavirus disease 2019 patients than for viral pneumonia patients admitted to ICU. Coronavirus disease patients also have longer time on ventilator and ICU length of stay, comparable with the subset of viral pneumonia patients with concurrent acute respiratory distress syndrome. Mortality and length of stay increase with age and higher scores in both populations, but observed to predicted mortality and length of stay are higher than expected with coronavirus disease patients across all severity of illness levels. These findings have implications for benchmarking ICU outcomes during the coronavirus disease 2019 pandemic.
目的:比较 2019 年冠状病毒病(COVID-19)检测呈阳性的成年重症监护病房(ICU)患者与因其他病毒性肺炎(包括病毒性肺炎合并急性呼吸窘迫综合征[病毒性肺炎-急性呼吸窘迫综合征]的亚组)入住 ICU 的患者的急性生理学与慢性健康状况评估系统第四版(APACHE IV)调整死亡率和住院时间结局。 设计:回顾性分析从常规临床护理中收集的 APACHE 数据。 设置:2020 年 3 月 14 日至 6 月 17 日期间,43 家医院向 COVID-19 患者数据,2014 年 1 月 1 日至 2019 年 12 月 31 日期间,美国 132 家医院向 APACHE 数据库中的原发性(n = 2544)或继发性(n = 1656)病毒性肺炎患者数据。单独检查了 202 例合并急性呼吸窘迫综合征的病毒性肺炎患者的亚组。 干预措施:无。 主要结果:COVID-19 患者的平均年龄为 63.4 岁(p = 0.064),而病毒性肺炎患者的平均年龄为 64.1 岁。APACHE IV 评分分别为 56.7 和 55.0,分别为 56.7 和 55.0(p = 0.060),但性别和种族分布不同,Pao2/Fio2 比值和入院时白细胞计数也不同。COVID-19 患者的医院标准化死亡率比(95%CI)为 1.52(1.35-1.68),病毒性肺炎患者为 0.82(0.75-0.90)。在 COVID-19 组中,ICU 和住院时间比病毒性肺炎患者长 3.1 天和 3.0 天。COVID-19 组的 ICU 和住院时间标准化比率分别为 1.13 和 1.46,而病毒性肺炎患者分别为 0.95 和 0.94。47%的 COVID-19 患者在 ICU 的第一天接受了有创或无创通气支持,而病毒性肺炎患者为 65%。在幸存者中,COVID-19 患者的呼吸机使用天数(10.4 天)长于病毒性肺炎患者(4.3 天),但病毒性肺炎-急性呼吸窘迫综合征亚组除外(10.2 天)。 结论:与入住 ICU 的病毒性肺炎患者相比,COVID-19 患者的严重程度调整死亡率和住院时间更长。COVID-19 患者的呼吸机使用时间和 ICU 住院时间也更长,与合并急性呼吸窘迫综合征的病毒性肺炎患者亚组相当。在这两个群体中,死亡率和住院时间随着年龄和评分的增加而增加,但在所有疾病严重程度水平上,COVID-19 患者的观察到的死亡率和住院时间预测值都高于预期。这些发现对在 COVID-19 大流行期间对 ICU 结局进行基准测试具有影响。
Cochrane Database Syst Rev. 2020-12-21
Healthc Inform Res. 2023-10
Antibiotics (Basel). 2023-4-3
Int J Environ Res Public Health. 2022-8-6
Indian J Crit Care Med. 2021-12